@prefix this: <http://www.tkuhn.ch/bel2nanopub/RANDJhyplvE-PkRvo-qvG_vYospabFy-O-q9Hp2U4jJTQ> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RANDJhyplvE-PkRvo-qvG_vYospabFy-O-q9Hp2U4jJTQ#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix go: <http://amigo.geneontology.org/amigo/term/GO:> .
@prefix nch: <http://resource.belframework.org/belframework/1.0/namespace/selventa-named-human-complexes/> .
@prefix ProteinComplex: <http://amigo.geneontology.org/amigo/term/GO:0043234> .
@prefix hasAgent: <http://semanticscience.org/resource/SIO_000139> .
@prefix RNA: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_33697> .
@prefix hgnc: <http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  nch:AP-1%20Complex a ProteinComplex: .
  
  sub:_1 hasAgent: nch:AP-1%20Complex;
    a go:0042789 .
  
  sub:_2 geneProductOf: hgnc:4421;
    a RNA: .
  
  sub:_3 occursIn: species:9606;
    rdf:object sub:_2;
    rdf:predicate belv:directlyDecreases;
    rdf:subject sub:_1;
    a rdf:Statement .
  
  sub:assertion rdfs:label "tscript(complex(NCH:\"AP-1 Complex\")) =| r(HGNC:GNRHR)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_5;
    pav:version "1.4" .
  
  sub:_4 prov:value "2 potential AP-1 binding sites located at positions -1000 to -994 and -943 to -937 was identified in the 248-bp fragment of the gonadotropin releasing hormone receptor (Gnrhr). A decrease in human GnRHR promoter activity was observed after GnRHa (GnRH agonists) treatment. GnRHa- and TPA-mediated decrease in the human GnRHR promoter activity was reversed by a specific protein kinase C inhibitor. These findings indicate that the activation of the PKC pathway is important in regulating the human GnRHR gene expression. EMSA studies with alphaT3-1 cells transfected with the Gnrhr reporter construct using anti-c-jun antibody demonstrated the binding of c-jun to the AP-1 binding site of the Gnrhr promoter. It was also demonstrated that mutation of the AP-1 binding site at -1000 to -994 abolished the GnRHa (GnRH agonists) induced inhibition. Thus, AP-1-binding site located at -1000 to -994 of the human GnRHR5'-flanking region has been identified to be involved in mediating the down-regulatory effect.";
    prov:wasQuotedFrom pubmed:11014215 .
  
  sub:_5 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:11014215;
    prov:wasDerivedFrom beldoc:, sub:_4 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:29:52.540+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}